ArticleFrontiers in pharmacology2023

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study.

Maxim Grymonprez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.